Celltrion acquires substance patent of Herceptin biobetter
Celltrion acquired a patent of the Antibody-Drug Conjugate(ADC) substance, a new drug treating breast cancer, from the Korean Intellectual Property Office on the 18th.
The patent, regarding its manufacturing method and anticancer composition making it active, is a patent for a Herceptin biobette...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
